174 - Generic Lenacapavir HIV Pre-Exposure Prophylaxis could be Produced for $25 Per Person Per Year

Co-Author(s)

• CF

  Cassandra Fairhead, MBBS

  Royal Free Hospital, London
  London, England, United Kingdom

Co-Author(s)

• JF

  Joseph Fortunak, PhD

  Department of Chemistry, Howard University, Washington, D.C., USA 20905
  Washington DC, District of Columbia, United States
• JL

  Jevon Layne, BS

  Johns Hopkins School of Medicine, 1650 Orleans St, RM162A, Baltimore, MD USA 21287
  Baltimore, Maryland, United States
• MJ

  Madison Johnson, BS

  Department of Chemistry, Howard University, Washington, D.C., USA 20905
  Washington DC, District of Columbia, United States
• SS

  Samyah Smalley, BS

  Department of Chemistry, Howard University, Washington, D.C., USA 20905
  Washington DC, District of Columbia, United States
• AL

  Andrew Lutterodt, BS

  QIAGEN, Frederick MD USA 20874
  Frederick, Maryland, United States
• DR

  David Roberts, BS

  – Department of Chemistry, Howard University, Washington, D.C., USA 20905
  Washington DC, District of Columbia, United States
• ET

  Endalkachew Tadesse, BEd

  Department of Chemistry, Howard University, Washington, D.C., USA 20905
  Washington DC, District of Columbia, United States
• JL

  Jasmine Lu, BS

  Lu Global Consulting, South Brunswick NJ, USA 08824
  South Brunswick, New Jersey, United States
• EP

  Eloan Pinheiro, PhD

  Consultant, ARV development and manufacturing, Rio de Janeiro, Brazil 22753-806
  Rio de Janeiro, Rio de Janeiro, Brazil
• MW

  Messay Wolde-Mariam, MSc

  Pharmaceutical Industry Development Sector, Armauer Hansen Research Institute, Addis Ababa, Ethiopia
  Addis Ababa, Adis Abeba, Ethiopia

Presenting Author(s)

• 

  Andrew Hill, PhD

  University of Liverpool
  London, England, United Kingdom

  Slides

Co-Author(s)

• TP

  Toby Pepperrel, MBBS

  Biological and Environmental Sciences, University of Stirling, Stirling, Scotland
  Stirling, Scotland, United Kingdom